Table 1 Demographic data and clinical description for the patients with SCZ of European ancestry treated with lurasidone and placebo groups.
From: Genetic markers of early response to lurasidone in acute schizophrenia
Lurasidone | Placebo | ||
|---|---|---|---|
Number of patients (Male/Female) | 171 (115/56) | 63(46/17) | |
Clinical trials (Pearl1/Pearl2) | 119/52 | 63(44/19) | |
Number of subjects in dosage (40/80/120 mg) | 59/41/71 | N/A | |
Age (years, mean ± S.D.) | 40.6 ± 11.0 | 38.4 ± 9.80 | |
Duration of Treatment (days) | All subjects | 32.8 ± 13.4 | 32.8 ± 13.3 |
Non-Completers | 16.6 ± 9.1 | 16.7 ± 8.4 | |
Number and % in treatment per week | Week 4 | 120 (70.2) | 44 (69.8) |
Week 2 | 153 (89.5) | 58 (92.1) | |
Week 1 | 163 (95.3) | 60 (95.2) | |
PANSS Total | Baseline | 95.47 ± 8.81 | 97.32 ± 10.76 |
ΔChange at week 4 | −18.92 ± 13.16 | −17.82 ± 14.93 | |
ΔChange at week 2 | −11.96 ± 11.61 | −8.91 ± 13.26 | |
ΔChange at week 1 | −7.51 ± 8.88 | −5.88 ± 8.37 | |
